Questions of cost-effectiveness, vaccine efficacy and feasibility are yet to be answered
In the United States, routine immunisation of all healthy children aged 6–23 months against influenza has recently been introduced. The principal justification for this is the relatively high morbidity and mortality from this disease in very young children.1 The United States is also considering routine influenza immunisation of all children aged over 6 months, in view of the herd protection it would provide to the adult population.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
I thank Professor Peter McIntyre, Director of the National Centre for Immunisation Research and Surveillance, for his helpful suggestions on the manuscript.
Gerald Watts is a member of the advisory boards for Merck Sharp and Dohme, Pfizer and AstraZeneca in Australia.